Introduction {#s1}
============

Individuals with a positive family history (FH^+^) of alcohol use disorder (AUD) are themselves at elevated risk of developing AUD ([@CIT0006]). These individuals also have a tendency to experience greater reinforcing and stimulant effects, relative to dysphoric and sedating effects, of alcohol ([@CIT0014]). Given the complex pharmacology of alcohol, delineation of the underlying neurobiology of this mixed pattern of subjective responses may seem especially challenging. However, since N-methyl-D-aspartate receptors (NMDARs) are key regulators of the reinforcing and intoxicating effects of alcohol, and are functionally up-regulated following chronic ethanol treatment in animal studies ([@CIT0023]; see [@CIT0011]), one possibility is that this stimulant effect bias reflects altered NMDARs functioning within central reward pathways ([@CIT0022]). Support for this notion is found in studies examining the effects of ketamine, a high-affinity NMDAR antagonist, in those with historic and/or familial risk of AUD. For example, recently detoxified AUD patients exhibit blunted positive and negative psychosis-like responses, as well as insensitivity to the dysphoric effects of ketamine ([@CIT0012]).

A similar mixed pattern of subjective effects has been found in response to ketamine in healthy, non-dependent FH^+^ drinkers ([@CIT0011]; [@CIT0017]; [@CIT0024]). Low-affinity NMDAR antagonists also produce distinct subjective, behavioral, and neural responses in healthy individuals according to family history of AUD ([@CIT0007]; [@CIT0016]). These findings suggest that the alterations in NMDAR function underlying the distinct subjective responses to antagonists cannot be attributed to chronic exposure to high doses of ethanol alone (as in AUD patients; [@CIT0012]).

Like ketamine, nitrous oxide (N~2~O) is a dissociative anaesthetic and primarily an antagonist at the NMDAR ([@CIT0008]). Its therapeutic potential, based on NMDAR antagonism, has only recently been explored in relation to psychiatric disorders ([@CIT0015]; [@CIT0004]). In the current study we draw on recent work showing an increase in the subjective stimulant-to-sedative ratio following ketamine administration in people with an inherited vulnerability to AUD ([@CIT0024]). We examined whether subjective responses to N~2~O---potentially also reflecting heritable NMDAR dysregulation, as above---differed in FH^+^ individuals compared to those without such histories (FH^-^). Such a pattern might suggest a common neuropsychopharmacological substrate for the subjective effects of N~2~O and ketamine. Moreover, similarities to ketamine would support the use of N~2~O as a convenient and safe pharmacodiagnostic/therapeutic agent for interrogating/treating NMDAR dysregulation in neuropsychiatric disorders. This would be an important development given that the pharmacopoeia of NMDAR-ergic agents is currently very small, its use limited (at least in the case of ketamine) by the potential for acute psychotomimetic and dysphoric effects, and the need for careful monitoring of such effects. N~2~O produces similar effects, though they are milder and reverse within minutes of terminating inhalation.

Material and Methods {#s2}
====================

The study was approved by University College London Research Ethics Committee. All participants provided written, informed consent and all procedures were carried out in accordance with the Declaration of Helsinki code of ethics for experiments involving human subjects. The data described here are part of a larger dataset from a study on the effects of N~2~O on reconsolidation of alcohol-related memories. Participants attended three sessions separated by at least 48 hs. The data presented here is primarily from session 2, the only session during which any drug (N~2~O) was administered.

Procedure {#s3}
---------

Prior to attendance, participants underwent a screening interview to establish eligibility. They also completed standardized alcohol-related assessments (e.g. measures of alcohol consumption and craving) and assessment of family history prior to attending session 2. After taking a breathalyzer test (Lion 500 portable Alcometer; Lion Instruments) at the beginning of session 2 (all gave a reading of 0.00), participants completed baseline subjective state measures, inhaled N~2~O for 10min, and then repeated the subjective state assessments while continuing to inhale N~2~O.

Participants {#s4}
------------

Eligibility criteria included: an absence of current psychiatric disorder; no use of psychotropic medication; no history of drug and alcohol dependence (as assessed using the alcohol module of the Structured Clinical Interview for DSM IV); an absence of any medical contraindications to use of N~2~O; aged 18--50 years; scoring \>8 on the Alcohol Use Disorders Identification Test (AUDIT; [@CIT0001]); and regularly drinking more alcohol than the UK government recommended maximum (112 and 168g/week for women and men, respectively). As such, participants were at risk of developing AUD on the basis of current drinking patterns and AUDIT scores. This risk of transitioning from heavy to disordered alcohol use is underscored by participants' mean age ([Table 1](#T1){ref-type="table"}), which is within the range of greatest relevance for such transition ([@CIT0010]). Sixty individuals met criteria and attended experimental sessions. They were classified as either FH^+^ (n = 23) or FH^-^ (n = 37; see below).

###### 

Demographic and Alcohol-Related Variables for Participants Without (FH^-^) and With (FH^+^) a Family History of Alcohol Problems.

                                    FH-               FH+
  --------------------------------- ----------------- -----------------
  Women: n(%)                       16 (43%)          7 (30%)
  Age (years)                       25.95 (8.14)      26.78 (9.00)
  AUDIT score                       13.68 (3.49)      16.35 (5.80)
  Alcohol (g/week)                  315.55 (149.55)   298.63 (103.53)
  Tonic craving (ACQ-Now)           32.14 (8.65)      34.11 (6.81)
  Picture rating (alcohol liking)   6.60 (1.07)       6.33 (1.21)
  Picture rating (alcohol urge)     5.76 (1.14)       5.73 (1.26)
  Depression (HADS)                 2.51 (2.47)       3.04 (3.23)
  Anxiety (HADS)                    6.57 (3.72)       5.83 (3.34)

Except for number (proportion) of women, values are means (± standard deviations). ACQ-Now, Alcohol Craving Questionnaire-Now; AUDIT, Alcohol Use Disorders Identification Test; HADS, Hospital Anxiety and Depression Scale.

Baseline Alcohol-Related Assessments {#s5}
------------------------------------

Baseline group differences were examined across a variety of alcohol-related measures. Alcohol consumption was assessed using the one week Timeline Followback (TLFB) procedure ([@CIT0021]). An infographic was provided to orient participants to alcohol quantities in typical drinks (in terms of UK units), which are expressed as grams of pure alcohol in this report.

Tonic craving at baseline was assessed using the 12-item Alcohol Craving Questionnaire-Now (ACQ-Now; [@CIT0020]), and cue-elicited drinking urge and stimulus pleasantness, using an alcohol picture rating task. Pleasantness and urge ratings were on a 0 = "extremely unpleasant/greatly decreases" to 10 = "extremely pleasant/greatly increases" scale.

Given that exploration of heritability was a secondary aim in this study, a brief assessment of family history was deemed to be more suitable than a full familial-diagnostic interview. As such, participants were asked to indicate which, if any, relatives within the family tree of first- and second-degree maternal and paternal family members in the current and previous two generations had experienced alcohol-related problems ([@CIT0013]). Importantly, such brief assessment methods perform nearly as well as full-scale measures of family history, with high levels of agreement between family members ([@CIT0019]). Participants were classified as FH^+^ if they identified either (or both) biological parent(s), or FH^-^ otherwise.

Mood and Anxiety {#s6}
----------------

The Hospital Anxiety and Depression Scale was used to gauge levels of depressed mood and anxiety ([@CIT0025]).

Subjective Response to Nitrous Oxide {#s7}
------------------------------------

A 12-item visual analogue Bodily Symptoms Scale (BSS; recorded on a 0--100 scale), reflecting expected N~2~O effects, and the participant-rated items of the Clinician Administered Dissociative States Scale (CADSS; [@CIT0002]) were used to assess subjective states immediately before (baseline) and after 10 mins of N~2~O inhalation. Our interest related to responses to the euphoria and drowsiness items, which, following Yoon and colleagues, were expressed as a single stimulant-to-sedative ratio ([@CIT0024]) at baseline and during-N~2~O inhalation.

Nitrous Oxide Administration {#s8}
----------------------------

We administered 50% N~2~O in oxygen (Entonox, British Oxygen Company) via an Ultraflow demand valve regulator (BPR Medical Ltd) for a total of 30min. Participants remained in the department for 30min after the end of the experiment to ensure N~2~O effects had completely worn off and they were well-oriented to time and place before leaving the department.

Statistical Analysis {#s9}
--------------------

Data was analyzed using SPSS version 22 (IBM) and, unless indicated, is presented as mean ± standard error of the mean throughout. Variables were examined for normality of distributions. Negatively skewed (stimulation-to-sedation ratio) data were +1 log transformed prior to a mixed factorial 2 (time as baseline; during N~2~O) x 2 (group as FH^+^ or FH^-^).

For ease of interpretation, raw (untransformed) values (which produced the same statistical outcome as transformed values) are shown in [Figure 1](#F1){ref-type="fig"}. These between-/within-subject factors were also used in the analysis of CADSS data. Significant interactions were explored using Bonferroni corrected pair-wise post hoc tests. Independent sample *t*-tests were used to compare the groups' baseline characteristics. Where the assumption of equality of variance was violated for independent sample *t*-tests, statistical correction was applied, and *t*-values and *dfs* adjusted accordingly. A small amount of missing data (\~6%) is reflected in lower degrees of freedom in the reported analysis than expected for the sample size.

![Ratio of stimulant to sedative effects of nitrous oxide (N~2~O) inhalation in participants without (FH^-^) and with (FH^+^) a family history of alcohol problems at baseline and during N~2~O inhalation. Bars represent (untransformed) estimated marginal means and associated standard errors of the means.](pyw06301){#F1}

Results {#s11}
=======

FH^+^ and FH^-^ groups had similar mean ages and gender composition. There were no significant differences between FH^+^ and FH^-^ groups on any alcohol- or affect-related variables (χ- or *t*-values ≤ 2; *p*-values \>0.05; [Table 1](#T1){ref-type="table"}).

There was a significant three-way interaction between time (pre- or during N~2~O), family history (FH^+^, FH^-^), and scale \[stimulation, sedation; F(1,54) = 6.98, *p* = 0.011, $\eta_{\text{p}}^{2}$ = 0.115\]. Pairwise, Bonferonni corrected post hoc tests comparing pre- and during N~2~O stimulation levels showed that FH^-^ participants did not experience a significant increase in stimulation (mean change ± SEM: +7.35±6.01; *p* \> 0.1), whereas FH^+^ participants did (+20.23±7.47; *p* = 0.009). Similarly, while there was a small non-significant increase in sedation among FH^-^ individuals (+5.68±5.33; *p* \> 0.1), a relatively large decrease in sedation from pre- to during N~2~O (-16.36±6.23; *p* = 0.017) was found in FH^+^ participants.

To allow a more direct comparison with the pattern of effects described with ketamine ([@CIT0024]), the simultaneous effects of N~2~O on stimulation and sedation were also expressed and analyzed as a stimulant-to-sedative ratio. As expected, a significant Time x Group interaction \[F(1,54) = 7.91, *p* \< 0.01, $\eta_{\text{p}}^{2}$ = 0.128\] was found on these ratio scores ([Figure 1](#F1){ref-type="fig"}), with post hoc tests showing that an increase in stimulation-to-sedation from baseline to during N~2~O was only observed in FH^+^ participants (*p* \< 0.01).

In contrast, CADSS scores showed only a main effect of Time, reflecting similar increases from baseline to during N~2~O in the FH^-^ (+15.53±2.02) and FH^+^ \[+14.39±2.53; F(1,57) = 85.63, *p* \< 0.01\].

Discussion {#s12}
==========

In this study we examined whether healthy individuals without alcohol dependence, but with a positive family history of alcohol problems, showed a similar pattern of subjective responses following N~2~O to those reported in other studies following ketamine administration ([@CIT0011]; [@CIT0017]; [@CIT0024]). In fact, the pattern we observed on the stimulant-to-sedative ratio measure was strikingly similar to the Group (FH^+^/FH^-^) by Time (pre-/during drug) interaction observed with ketamine ([@CIT0024]). It is possible that the overlapping *in vitro* neuropharmacology of N~2~O and ketamine ([@CIT0009]) underlies this similarity. More specifically, this common pattern of subjective responses in FH^+^ individuals is consistent with the notion that altered responses to dissociative-anaesthetic NMDAR antagonists are a potential pharmaco-endophenotype reflecting intergenerational transmission of dysregulated NMDAR function underlying AUDs. A full determination of the endophenotype-status of such responses requires further research, although, as with alcohol, the subjective response to N~2~O possesses at least some of the characteristics expected of an endophenotype ([@CIT0014]). Alternatively (or in addition), N~2~O response in FH ^+^ participant may reflect epigenetic influences or chronic neural dysregulation resulting from developmental adversity (arising from one or both parents' excessive drinking). Previous research has partially addressed this concern by not including FH^+^ participants with alcohol-dependent mothers, thus at least reducing the possibility that pre-natal exposure to toxic alcohol effects contributed to differential responses in FH^+^ participants (e.g. [@CIT0017]).

While we cannot rule out the possibility that the observed effects of N~2~O reflect its action on neurotransmitter systems other than NMDARs, the established receptor-level pharmacological similarities and the convergence of findings from human psychopharmacological studies across various NMDAR antagonists makes an NMDAR-mediated account of the current findings the most parsimonious. If our findings do reflect the action of N~2~O on a heritable dysregulated NMDAR system, they suggest that research participants are reliably able to identify this dysregulation through its ultimate expression: namely, in the behavior of their relatives. In addition, the results potentially indicate that expression of NMDAR dysfunction in FH^+^ individuals is associated with a lower threshold of problem severity (among relatives) than has been implied by previous studies with ketamine, in which FH^+^ participants were those with alcohol-dependent family members ([@CIT0017]; [@CIT0024]).

Our findings have potentially important clinical implications. For example, an appraisal of family history of alcohol problems may be important when determining the suitability of N~2~O (or other NMDAR antagonists) as a treatment for depression ([@CIT0018]; [@CIT0015]), post-traumatic stress disorder ([@CIT0004]), and addictions ([@CIT0005]). Given the recent surge of interest in NMDAR antagonists as novel pharmacotherapeutics for major depressive disorder ([@CIT0003]; [@CIT0015]), an improved understanding of predictors of NMDAR antagonist responses will be key for understanding variability in treatment and may facilitate the development of personalized interventions for depression. Despite these possibilities, it is important to extend our preliminary findings. For example, a future study should use standardized assessments of subjective drug effects, and assess the similarity of N~2~O's effects to those of alcohol (e.g. using the biphasic alcohol effects scale; [@CIT0024]).

In sum, the subjective response to N~2~O may be an efficient and convenient pharmacological probe that signals NMDAR dysfunction and in turn, increased risk of neuropsychiatric disorders or probable treatment response. While evidence mounts that ketamine is a valuable and potent probe drug and pharmacotherapeutic agent, there continues to be a need for effective, easily-administered, and rapidly-reversing NMDAR antagonists for use in the prognostics and treatment of neuropsychiatric disorders. N~2~O appears to have these properties.
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